HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment
Breast Cancer Update
00:00
What payloads do current ADCs use and are non-chemotherapy payloads possible?
Dr Huppert reviews topo‑1 payload dominance, other payload classes, and potential non‑chemotherapy payloads like radioisotopes or immunomodulators.
Play episode from 04:30
Transcript
